Dexfadrostat ((R)-Fadrozole) is a potentnonsteroidalinhibitor^[1]. Dexfadrostat also inhibits human placentalaromatase(pIC₅₀= 6.17) and aldosterone biosynthesis. Dexfadrostat reverses cardiac fibrosis in spontaneously hypertensive heart failure rats.^[1][2].

pIC50: 6.17 (human placental aromatase)

The (-)-enantiomer with the S-absolute configuration was responsible for the high aromatase inhibitory activity of Dexfadrostat^[1].

Dexfadrostat ((R)-fadrozole; 0.24 and 1.2 mg/kg; daily; oral) and (S)-fadrozole similarly decreases plasma aldosterone levels, whereas urinary aldosterone excretion rate was reduced only by S-fadrozole^[2].
Dexfadrostat (0.24 and 1.2 mg/kg; daily; oral) effectively reverses preexistent left ventricular interstitial fibrosis by 50% (vs. 42% for canrenoate), S-fadrozole was devoid of an antifibrotic effect^[2].

223.27

C₁₄H₁₃N₃

102676-87-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.